Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Microbot Medical Inc. (NASDAQ: MBOT), a commercial stage medical device company focused on the LIBERTY Endovascular Robotic System. Through these filings, investors can review how the company reports material events, financing transactions, intellectual property developments and key commercialization steps for its endovascular robotics platform.
Microbot Medical uses current reports on Form 8-K to disclose significant milestones, including FDA 510(k) clearance for the LIBERTY System, the start of its limited market release in the U.S., and the first hospital adoption of LIBERTY for patient care at Emory University Hospital. Other 8-K filings describe partnerships with a U.S.-based third-party logistics provider to support commercialization, as well as the company’s exhibition of LIBERTY at major medical meetings.
Several 8-K filings also detail capital markets activity, such as the exercise of outstanding preferred investment options, issuance of new short-term preferred investment options and related gross proceeds. In these documents, Microbot Medical outlines intended uses of funds, including continued development, commercialization and regulatory activities for the LIBERTY Robotic System, potential acquisitions of complementary assets or products, expansion of applications derived from its IP portfolio, and working capital and general corporate purposes.
Additional filings address intellectual property events, such as the granting of the company’s first patent in Japan covering core LIBERTY System technology, and certain compensation decisions for executives and non-management directors. On Stock Titan, these filings are updated as they are made available through EDGAR, and AI-powered summaries can help explain the context and key points of each document, from material event disclosures to financing terms and governance changes related to MBOT.
Microbot Medical Inc. (Nasdaq: MBOT) filed a Form S-8 on 21 Jul 2025 to register an additional 3,791,019 common shares for issuance under its 2020 Omnibus Performance Award Plan. The pool was last expanded by 2,591,019 shares approved on 10 Jun 2025. The filing is made under General Instruction E and incorporates the company’s prior S-8 (File No. 333-250963).
The registration statement also includes a re-offer prospectus for up to 2,009,697 shares underlying options held by directors and officers that may be resold on a continuous basis under Rule 415. No proceeds will accrue to the company; any sales will be effected by the holders. With 39,991,652 shares outstanding, the newly registered shares equal roughly 9.5% potential dilution, while the re-offer covers about 5.0% of current float.
Corporate updates inside the prospectus note key milestones: 510(k) submitted for the fully disposable LIBERTY® Endovascular Robotic System (10 Dec 2024) with FDA clearance targeted for Q3 2025 and U.S. launch immediately thereafter; ISO 13485 certification obtained Aug 2024; CE-Mark expected 2H 2026. A $4.82 m ATM program (4.28 m shares) has been completed, and management states that ongoing regional conflicts have not yet produced material operational effects.